AstraZeneca's Bold Revenue Growth Plans and Strategic Investments

Exploring AstraZeneca's strategic plans for achieving 7% to 8% top-line growth through a diverse portfolio focused on oncology, rare diseases, metabolic disorders, and respiratory issues, including the launch of 20 new medicines and investments in cutting-edge technologies like cell therapy and antibody drug conjugates.